Hengrui Medicine First-Half Profit RMB4.465 Billion, Up 0.3%; Revenue Down 1.9%; Shares Down Over 9%
Hengrui Medicine reported first-half profit attributable to shareholders of RMB4.465 billion, up 0.3% year on year, while revenue fell 1.9% to RMB15.456 billion. The company declared no interim dividend. Shares dropped 9.6% to HK$49.66 at 3:17 p. m. , after declining as much as 11.2% intraday to a low of HK$48.80. Earnings per share were RMB0.68, and gross margin narrowed 0.3 percentage point to 86.3%.
After Hengrui Medicine released its interim results, its share price fell sharply, with an intraday decline of up to 11.2% to a low of HK$48.80. As of 3:17 p. m. , the stock was trading at HK$49.66, down 9.6%, with turnover exceeding HK$1.19 billion.
According to the company's disclosed figures, for the interim period ended June 2026, profit attributable to shareholders was RMB4.465 billion, up 0.3% year on year; earnings per share were RMB0.68, with no dividend declared. Revenue for the period was RMB15.456 billion, down 1.9% year on year. Gross margin was 86.3%, down 0.3 percentage point year on year.